Viking Therapeutics (VKTX) is identified by Oppenheimer among five potential biotech M&A candidates ahead of J.P. Morgan Healthcare Conference. Read more here.
Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer ...
While customer-friendly outcomes are creating greater investor pushback, Oppenheimer believes hold pressures are transitory and remains a buyer on weakness. Oppenheimer has an Outperform rating ...